Inozyme Targets Underserved Mineralization Disorders Market With First-In-Class Enzyme Therapy

 
• By Ayisha Sharma
  
Emerging Company Profile: Inozyme Pharma
ENPP1 Deficiency Can Cause Arterial Calcification And Eventual Death • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Emerging Company Profiles

More from Start-Ups & SMEs